Growth Metrics

Idexx Laboratories (IDXX) EBIT Margin (2016 - 2026)

Idexx Laboratories has reported EBIT Margin over the past 17 years, most recently at 28.94% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 152.0% year-over-year to 28.94%; the TTM value through Dec 2025 reached 31.6%, up 265.0%, while the annual FY2025 figure was 31.6%, 265.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 28.94% at Idexx Laboratories, down from 32.11% in the prior quarter.
  • Over five years, EBIT Margin peaked at 33.62% in Q2 2025 and troughed at 20.81% in Q2 2022.
  • A 5-year average of 29.25% and a median of 29.88% in 2022 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: tumbled -1057bps in 2022 and later skyrocketed 1058bps in 2023.
  • Year by year, EBIT Margin stood at 24.86% in 2021, then rose by 10bps to 27.34% in 2022, then decreased by 0bps to 27.21% in 2023, then rose by 1bps to 27.42% in 2024, then rose by 6bps to 28.94% in 2025.
  • Business Quant data shows EBIT Margin for IDXX at 28.94% in Q4 2025, 32.11% in Q3 2025, and 33.62% in Q2 2025.